SNX4 Antibody

What is SNX4 and what cellular processes does it regulate?

SNX4 is an evolutionary conserved protein that mediates recycling from endosomes back to the plasma membrane in yeast and mammalian cells. It is expressed in the brain, where it has been found to co-localize with both early and recycling endosome markers . In neurons, SNX4 accumulates specifically in synaptic areas, with a predominant localization to presynaptic terminals . Recent research has identified SNX4 as a negative regulator of synaptic vesicle docking and release, suggesting a role in synaptic vesicle recruitment at the active zone . Additionally, SNX4 is required for proper autophagic flux and localizes to LAMP1-positive endolysosomes and EEA1-positive early endosomes in a PI3P-dependent manner . Altered SNX4 protein levels have been associated with Alzheimer's disease, with protein levels decreased by approximately 70% in brains of severe Alzheimer's disease cases .

What are the available SNX4 antibodies for laboratory research?

Several SNX4 antibodies are available for research applications, though they vary in specificity and application suitability. Commercially available antibodies against SNX4 typically only detect mouse SNX4 by western blot . A novel antibody developed in collaboration with Synaptic Systems (Cat. No. 392 003) against the N-terminal region of mouse SNX4 has demonstrated specificity for both western blot and immunocytochemistry applications . This antibody detects a protein of approximately 50 kDa, which corresponds with the expected size of SNX4 . When selecting an SNX4 antibody, researchers should consider the specific application (western blot, immunocytochemistry, or immunohistochemistry) and the species of interest, as antibody compatibility varies significantly across these parameters.

What is the subcellular localization pattern of SNX4 in neurons?

In neurons, SNX4 displays a distinctive subcellular localization pattern that differs somewhat from non-neuronal cells. Using specific antibodies, endogenous neuronal SNX4 has been shown to co-localize with both early endosome marker RAB5 (Pearson's coefficient 0.58) and recycling endosome marker RAB11 (Pearson's coefficient 0.45) . Notably, SNX4 accumulates specifically in synaptic areas, with immunoreactivity showing strong colocalization with synaptophysin-1 (Pearson's coefficient 0.71) . Subcellular fractionation studies of mouse hippocampus have detected SNX4 in the synaptosome (SyS) fraction and synaptic membrane fraction (SyM), but it is not enriched in the postsynaptic density (PSD) fraction . Immuno-gold electron microscopy has confirmed this distribution, showing gold particles inside presynaptic terminals and on the postsynaptic membrane in close proximity to the postsynaptic density . Quantitative analysis demonstrated that SNX4 immunosignal is more abundant in the presynaptic than the postsynaptic terminal .

What validation methods should be used to confirm SNX4 antibody specificity?

When validating SNX4 antibody specificity, researchers should implement multiple complementary approaches:

• Knockdown/knockout validation: Develop independent short hairpin RNAs (shRNAs) against SNX4 and rescue constructs. The antibody should detect decreased signal intensity upon SNX4 knockdown, with restored levels when combined with corresponding rescue constructs . For more definitive validation, conditional knockout models can be used, as demonstrated by researchers who achieved 90% SNX4 reduction after 21 days of Cre expression in a conditional knockout mouse model .

• Western blot analysis: The antibody should detect a protein band of approximately 50 kDa, corresponding to the expected size of SNX4 . Compare results with commercially available antibodies to confirm consistent band detection.

• Cross-validation with mass spectrometry: Mass spectrometry can verify SNX4 reduction following knockdown, providing quantitative confirmation of antibody specificity .

• Immunocytochemistry pattern assessment: Specific SNX4 antibodies should show a punctate labeling pattern in neuronal cultures, with significantly decreased signal in knockdown conditions .

• Negative controls: Include appropriate negative controls, such as blocking peptides, to confirm absence of non-specific binding .

What are the optimal conditions for using SNX4 antibodies in western blot applications?

For optimal western blot detection of SNX4, researchers should consider the following parameters:

• Sample preparation: For neuronal samples, harvest cells at DIV14-15 (14-15 days in vitro) for optimal SNX4 detection . When working with brain tissue, SNX4 can be detected across various brain regions including hippocampus .

• Detection sensitivity: The specific antibody developed against the N-terminal region of mouse SNX4 (Synaptic Systems Cat. No. 392 003) can detect endogenous levels of SNX4 in neuronal lysates . Be aware that this antibody may also detect a lower non-specific band of approximately 30 kDa that remains unaffected by SNX4 knockdown .

• Controls: Include positive controls (brain tissue lysates) and negative controls (SNX4 knockdown samples) to validate specificity . When performing knockdown studies, include rescue constructs to confirm antibody specificity .

• Signal quantification: For accurate quantification of SNX4 levels, normalize to appropriate housekeeping proteins and use multiple biological replicates to account for variability in expression levels .

How should SNX4 antibodies be used for immunocytochemistry in neuronal cultures?

When using SNX4 antibodies for immunocytochemistry in neuronal cultures, researchers should follow these methodological guidelines:

• Fixation protocol: Fix primary neuronal cultures at DIV14-15 to ensure optimal detection of synaptic SNX4 . This timing allows for proper synapse formation and SNX4 accumulation at synaptic terminals.

• Co-labeling strategy: Co-label with synaptophysin-1 or bassoon (presynaptic markers) to confirm synaptic localization of SNX4 . For endosomal localization, co-label with RAB5 (early endosome marker) or RAB11 (recycling endosome marker) .

• Signal detection: Expect a punctate pattern of SNX4 immunolabeling in neuronal cultures, with enrichment in synaptic areas . Use confocal microscopy with appropriate resolution to distinguish synaptic from non-synaptic SNX4 puncta.

• Quantification methods: For colocalization analysis, calculate Pearson's correlation coefficients between SNX4 and marker proteins (e.g., RAB5, RAB11, synaptophysin-1) . For knock-down validation, measure total SNX4 signal intensity across neuronal processes and compare to control conditions .

How does SNX4 knockdown or knockout affect the neuronal proteome?

SNX4 knockdown or knockout has significant effects on the neuronal proteome that extend beyond its direct cargo proteins. Quantitative mass spectrometry analysis of SNX4 knockdown neurons revealed that the class of proteins involved in neurotransmission was the most dysregulated . This included integral membrane proteins at both the presynaptic and postsynaptic sides of the synapse that participate in diverse synaptic processes such as synapse assembly, neurotransmission, and the synaptic vesicle cycle .

A proteomics study of multiple independent SNX4 knockdowns using different shRNAs identified 290, 167, and 283 dysregulated proteins in three different shRNA conditions compared to control . Among these, 13 proteins showed consistent dysregulation across all three knockdown conditions, with 4 up-regulated and 9 down-regulated proteins . Hierarchical clustering analysis demonstrated that expression of each individual SNX4-targeted shRNA results in a distinct and reproducible neuronal proteome profile .

Researchers investigating SNX4's effects on the proteome should employ:

• Multiple independent knockdown/knockout approaches to distinguish on-target from off-target effects

• Comprehensive quantitative proteomics techniques like LC-MS/MS

• Appropriate statistical analysis to identify consistently dysregulated proteins

• Pathway and functional enrichment analysis to determine affected cellular processes

What are the discrepancies between shRNA-mediated knockdown and genetic knockout models of SNX4?

Significant discrepancies have been observed between shRNA-mediated knockdown and genetic knockout approaches for studying SNX4 function. Researchers have reported off-target effects using shRNA approaches, which led to the development of conditional knockout mouse models for SNX4 . These off-target effects might explain some inconsistencies in reported SNX4 functions across different studies.

When comparing these approaches:

• Knockdown efficiency: In neuronal cultures, SNX4 conditional knockout achieved 90% protein reduction after 21 days of Cre expression, compared to variable efficiencies with shRNA approaches (typically 60-80%) .

• Temporal considerations: SNX4 has a half-life of approximately 10.6 days in neuronal cultures , requiring extended periods for effective protein depletion. Conditional knockout studies showed 67% reduction after 14 days of Cre expression, 83% after 18 days, and 90% after 21 days .

• Cargo trafficking effects: While yeast studies suggested that the SNX4 homologue Snx4p mediates retrieval of VAMP2/synaptobrevin-2 homologue, investigations in SNX4 conditional knockout neurons found no significant differences in VAMP2/syb-2 puncta number or intensity, contrary to some shRNA study findings .

Researchers should consider these discrepancies when designing experiments and interpreting results, potentially using both approaches when feasible to distinguish genuine phenotypes from methodological artifacts.

How does SNX4 dysfunction contribute to neurodegenerative diseases like Alzheimer's?

SNX4 dysfunction has been implicated in neurodegenerative diseases, particularly Alzheimer's disease (AD), through several molecular mechanisms:

• Altered protein levels: SNX4 protein levels are decreased by approximately 70% in brains of severe Alzheimer's disease cases , suggesting a potential role in disease pathogenesis or progression.

• Beta-secretase 1 (BACE-1) trafficking: SNX4 dysregulation has been shown to mistarget BACE-1 to late endosomal compartments, which impacts amyloid-β (Aβ) production . BACE-1 is a critical enzyme involved in the proteolytic processing of amyloid precursor protein, leading to the formation of pathological Aβ peptide in AD .

• Synaptic protein regulation: SNX4 knockdown dysregulates numerous proteins involved in synaptic transmission , which could contribute to synaptic dysfunction observed in early stages of AD.

• Endosomal trafficking defects: As SNX4 coordinates recycling from early endosomes to the plasma membrane through recycling endosomes , its dysfunction may disrupt endosomal trafficking pathways that are increasingly recognized as central to AD pathogenesis.

Researchers investigating SNX4's role in neurodegenerative diseases should:

• Examine SNX4 levels and localization in patient samples and animal models of disease

• Investigate the effects of SNX4 modulation on pathological markers like Aβ production

• Explore potential therapeutic approaches targeting SNX4-mediated trafficking pathways

• Consider SNX4 dysfunction in the context of other endosomal proteins implicated in neurodegeneration

What genetic tools are available for manipulating SNX4 expression in experimental models?

Several genetic tools have been developed for manipulating SNX4 expression in experimental models:

• Short hairpin RNAs (shRNAs): Multiple independent shRNAs targeting SNX4 have been developed and validated. Target sequences include "GGG AAT GAC TAC CAA ACT C" (shSNX4-1), "GCA GTG GAA TAG ATA CAT TAT" (shSNX4-2), and "GCT GAT ATT GAA CGC TTC AAA" (shSNX4-3) . These can be delivered via lentiviral vectors under U6 promotor control, along with reporter genes like mCherry under the synapsin promotor to identify transduced neurons .

• Rescue constructs: Mouse SNX4 cDNA with silent point mutations has been used to generate rescue constructs resistant to shRNA degradation . These constructs allow for verification of phenotype specificity by demonstrating rescue of shRNA-induced effects.

• Conditional knockout mouse model: A conditional knockout mouse model for SNX4 has been generated to circumvent off-target effects observed with shRNA approaches . This model allows for temporal control of SNX4 deletion using Cre-loxP technology.

• Expression vectors: For overexpression studies, stable cell lines expressing tagged versions of SNX4 (e.g., mNeonGreen–SNX4) have been developed for live imaging applications .

When selecting genetic tools for SNX4 manipulation, researchers should consider:

• The temporal requirements of their experiment (acute vs. chronic depletion)

• The cellular context (in vitro neuronal cultures, non-neuronal cell lines, in vivo models)

• The need for tissue-specific or inducible expression/deletion

• The potential for off-target effects, particularly with RNAi approaches

What techniques are most effective for studying SNX4-mediated protein trafficking?

To effectively study SNX4-mediated protein trafficking, researchers should consider these methodological approaches:

• Live-cell imaging: Stable cell lines expressing fluorescently tagged SNX4 (e.g., mNeonGreen–SNX4) enable visualization of SNX4-positive compartments in real-time . This approach allows for tracking of cargo protein movement through SNX4-positive compartments.

• Co-localization analysis: Immunostaining for SNX4 together with endosomal markers (RAB5, RAB11) and potential cargo proteins allows for quantitative assessment of protein co-localization using Pearson's correlation coefficients . This approach has successfully demonstrated SNX4 localization to both early and recycling endosomes.

• Subcellular fractionation: Isolation of different subcellular compartments (e.g., synaptosome, synaptic membrane, postsynaptic density fractions) followed by western blot analysis can reveal the distribution of SNX4 and its potential cargo proteins across cellular compartments .

• Immuno-gold electron microscopy: This high-resolution technique can precisely localize SNX4 at the ultrastructural level, as demonstrated by studies showing preferential localization of SNX4 to presynaptic terminals over postsynaptic sites .

• Cargo trafficking assays: Following specific cargo proteins (e.g., ATG9A) after SNX4 manipulation can reveal trafficking defects. Studies have shown that the percentage of LAMP1-positive vesicles containing ATG9A increases in SNX4 siRNA-treated cells, while ATG9A co-localization with early-endosomal marker EEA1 decreases .

• Proteomics approaches: Quantitative mass spectrometry before and after SNX4 depletion can identify proteins whose cellular distribution or levels are affected by SNX4 , providing insights into potential cargo proteins.

What experimental design considerations are important when studying SNX4 in neuronal systems?

When designing experiments to study SNX4 in neuronal systems, researchers should consider these critical factors:

• Neuronal maturation stage: SNX4 localizes to synaptic terminals, which develop over time in culture. Studies should be conducted in mature neurons (typically DIV14-15 or later) to ensure proper synaptic development . This timing allows for accurate assessment of SNX4's synaptic functions.

• SNX4 depletion timeline: Given SNX4's long half-life (10.6 days in neuronal cultures) , sufficient time must be allowed for protein depletion after genetic manipulation. Conditional knockout studies showed optimal depletion (90% reduction) after 21 days of Cre expression .

• Specificity controls: Multiple independent shRNAs and rescue constructs should be used to distinguish specific from non-specific effects . Alternatively, conditional knockout models provide a more specific approach to SNX4 depletion .

• Synaptic phenotype analysis: Given SNX4's role in synaptic function, experiments should assess multiple aspects of synaptic biology:

  • Structural changes in synaptic organization (using markers like synaptophysin-1 and bassoon)

  • Functional changes in neurotransmission

  • Alterations in synaptic protein composition through proteomics

  • Changes in synaptic vesicle docking and release

• Cell-type considerations: SNX4 is expressed throughout the brain , but its function may vary by neuronal subtype. Experiments should specify the neuronal population being studied (e.g., hippocampal neurons, cortical neurons) and consider potential cell-type specific effects.

• In vitro versus in vivo approaches: While cultured neurons provide a controlled environment for mechanistic studies, validation in intact circuits using conditional knockout animals can provide more physiologically relevant insights into SNX4 function .

How does SNX4 interact with the autophagy machinery in neurons?

Recent research has begun to uncover important connections between SNX4 and autophagy pathways. In non-neuronal cells, SNX4 has been shown to localize to LAMP1-positive endolysosomes and EEA1-positive early endosomes in a PI3P-dependent manner . SNX4 appears to be required for proper autophagic flux, with depletion causing disruptions in this process .

A key mechanism involves ATG9A trafficking. SNX4 knockdown leads to increased colocalization of ATG9A with LAMP1-positive vesicles (83.2%±1.3) and decreased colocalization with the early-endosomal marker EEA1 . This suggests that SNX4 is required for precise mobilization of ATG9A during autophagy, a protein critical for autophagosome formation.

In neuronal contexts, the relationship between SNX4 and autophagy requires further investigation, particularly given that:

• Autophagy dysfunction is implicated in numerous neurodegenerative disorders

• Neurons have specialized requirements for autophagy in synaptic compartments

• SNX4's predominant localization to presynaptic terminals suggests it may play a role in local autophagy regulation at synapses

Future research directions should explore:

• The specific role of SNX4 in neuronal autophagy

• How SNX4-mediated trafficking of ATG9A or other autophagy proteins might contribute to synaptic maintenance

• Whether SNX4 dysfunction in neurodegenerative diseases impacts neuronal autophagy

What is the relationship between SNX4 and other sorting nexin family members in neurons?

The relationship between SNX4 and other sorting nexin family members in neurons remains an important area for investigation. SNX4 belongs to a larger family of phosphoinositide-binding proteins that play diverse roles in endosomal sorting and trafficking pathways. While the search results don't provide specific information on SNX4's interactions with other family members in neuronal contexts, several research questions merit exploration:

• Functional redundancy: Do other sorting nexins compensate for SNX4 loss in knockout models? The relatively modest phenotypes observed in some SNX4 depletion studies might reflect functional redundancy within this protein family.

• Complex formation: In non-neuronal cells, SNX4 can form complexes with other sorting nexins. Whether similar complexes exist in neurons and how they might regulate specific cargo trafficking pathways requires investigation.

• Differential expression: Analysis of sorting nexin expression patterns across brain regions and neuronal subtypes could reveal complementary or antagonistic relationships between family members.

• Disease associations: While SNX4 levels are decreased in Alzheimer's disease , examining the relationship between SNX4 and other sorting nexins in disease contexts might reveal coordinated dysregulation of endosomal trafficking pathways.

Methodological approaches to address these questions could include:

• Co-immunoprecipitation studies to identify SNX4-interacting sorting nexins in neuronal contexts

• Comparative loss-of-function studies targeting multiple sorting nexins simultaneously

• Proteomic analysis of sorting nexin complexes in different neuronal compartments

What therapeutic potential exists in targeting SNX4 for neurodegenerative disorders?

The involvement of SNX4 in Alzheimer's disease pathways suggests potential therapeutic opportunities. Given that SNX4 protein levels are decreased by approximately 70% in brains of severe Alzheimer's disease cases , and that SNX4 dysregulation mistargets BACE-1 to late endosomal compartments affecting Aβ production , several therapeutic strategies might be considered:

• SNX4 stabilization or upregulation: Approaches to increase or stabilize SNX4 levels might correct trafficking defects in disease conditions. This could involve small molecules that stabilize SNX4 protein or gene therapy approaches to increase expression.

• Targeting specific SNX4-dependent trafficking pathways: Rather than modulating SNX4 directly, interventions targeting specific downstream trafficking pathways might prove beneficial. For example, correcting BACE-1 mislocalization could reduce pathological Aβ production.

• SNX4-inspired drug delivery strategies: Understanding SNX4-mediated trafficking pathways could inform the development of drug delivery systems that leverage these pathways to target therapeutic agents to specific neuronal compartments.

• Biomarker development: Changes in SNX4 levels or localization might serve as biomarkers for endosomal dysfunction in neurodegenerative diseases, potentially allowing for earlier diagnosis or monitoring of disease progression.

Challenges in developing SNX4-targeted therapeutics include:

• The broad expression pattern of SNX4 across tissues, potentially leading to off-target effects

• The long half-life of SNX4 protein (10.6 days) , which may necessitate sustained therapeutic intervention

• The complex role of SNX4 in multiple trafficking pathways, requiring careful consideration of pathway-specific interventions

Research strategies should focus on validating SNX4 as a therapeutic target in animal models of neurodegenerative disease before advancing to clinical applications.